Primary Health Properties PLC (PHP) — Research Note

Executive summary

PHP is the UK's largest listed primary healthcare REIT, owning a £6bn portfolio of 1,140 medical centres and private hospitals in the UK and Ireland, with 76% of rent backed directly or indirectly by the NHS/HSE. Following the August 2025 all-share combination with Assura, adjusted EPS rose 9% h/h to 3.8p in H1 2026, driven by scale, cost synergies (92% of £9m target delivered), and 3.2% annualised organic rental growth. The single most important valuation point today: shares trade at 94.45p vs Adjusted NTA of 104p — a modest 9% discount, so the market has already priced in the elevated LTV (57%, above 40–50% target) and Net Debt/EBITDA of 10.4x, which management is committed to reducing via a £0.7bn private-hospital JV expected to complete summer 2026.

Fair value estimate

• Fair value range: 95p – 108p per share → implied market cap £2,465m – £2,802m
• Methodology: NAV-based (primary for a REIT), cross-checked against dividend yield.
  • Adjusted NTA 104p (H1 2026). Peer UK healthcare/defensive REITs typically trade in a range of 0.9x–1.05x NAV depending on cost-of-debt trajectory and deleveraging progress.
  • Dividend yield check: 7.3p annualised dividend. At 6.75%–7.75% target yield (appropriate for a levered, government-backed income REIT in the current gilt environment), fair value = 94p–108p.
• Comparison to current £2,451m market cap: The mid-point (~101p / £2,633m) implies **+7% upside**. At the top end +14%, at the bottom end roughly flat.
• Absolute upside on mid-point: ~+7%.

Sector context

• Confirmed classification: Real Estate — Real Estate (UK REIT). Sub-sector: healthcare real estate infrastructure.
• Quality profile is above sector average: government-backed income (76%), 99% occupancy, 10.4y WAULT — but leverage (57% LTV, 10.4x Net Debt/EBITDA) is meaningfully above typical listed REIT averages.
• Listed peers: Assura (now merged into PHP) was the direct peer; wider comparables include Target Healthcare REIT (THRL) (care homes), LondonMetric (LMP) (defensive property), and internationally Medical Properties Trust (MPW) and Healthpeak (DOC).

Investment thesis (3 bullets)

• Sector-leading income security at scale, unmatched post-Assura: 76% government-backed, 99% occupancy, 10.4y WAULT, and rent reviews delivering 3.2% annualised growth in H1 2026 — one of the lowest EPRA cost ratios in UK REITs at 8.7% 2026-07-30 interim results.
• Structural tailwind from NHS 10-year plan: The plan's shift "from hospital to community" and the Neighbourhood Health Centres (NHC) programme underpin decades of demand for modern primary-care real estate; three PHP assets are already in the first NHC tranche 2026-07-30 interim results.
• De-leveraging catalyst path is credible and near-term: £0.7bn private-hospital JV due summer 2026, £103m USS transfer, plus £400m two-year facility completed post period end — proforma LTV drops to ~53% and management targets a BBB+ credit rating 2026-07-30 interim results; 2026-04-29 AGM update.

Key risks (3 bullets)

• Elevated balance-sheet risk: LTV 57%, Net Debt/EBITDA 10.4x, and cost of debt rising to 3.8% (from 3.7%). Interest cover has slipped to 2.6x from 2.8x. If the private-hospital JV slips or is priced below expectations, deleveraging targets are missed 2026-07-30 interim results.
• Rental growth capped by District Valuer: Open-market reviews still only delivering 2.0% annualised, well below cost-of-debt. Reversionary rent growth potential is real (£200 psm vs new-build £279 psm) but historically slow to crystallise via the DV process 2026-07-30 interim results.
• Refinancing risk in a rate-cut-postponed environment: Anticipated 2026 rate cuts "have not come to fruition and are expected to increase" per the interim commentary. The remaining £260m bridge and near-term maturities must be refinanced at wider spreads if rates stay elevated 2026-07-30 interim results.

Operating leverage

Operating leverage is limited but positive. As a REIT, revenue is contractually recurring rent; incremental revenue drops to profit primarily via (a) the low EPRA cost ratio (8.7%, ex-Axis) meaning ~91p of every incremental £1 of rent becomes NOI, and (b) fixed interest costs — so post-deleveraging, a 10% rent uplift could add roughly 20–25% to adjusted earnings via the interest leverage effect. Central administrative costs (£12m H1) are already very lean and largely fixed at the corporate level. However, the "long-tail upside" is intrinsically capped: reviews are contractual, mostly 3–5 yearly, DV-agreed, and physically constrained. A truly "10–20% revenue surprise" is not feasible in any single year for a REIT of this construction. The higher-leverage angle is NAV sensitivity: a 25bp NIY compression = ~£264m portfolio uplift = ~10p per share (~11%). Score: moderate operating leverage skewed toward NAV, not earnings.

Value-trap signals

• High LTV vs peers and vs own target range — 57% vs 40–50% target, sustained for over 12 months.
• IFRS EPS declined y/y (3.8p vs 4.4p) despite the merger, due to increased finance costs and MtM amortisation.
• Refinancing risk continually present given weighted-average debt maturity of 4.0 years and £260m acquisition bridge still outstanding.
• Share price has drifted lower for 12 months (down 1.8% y/y despite growing dividend and stable NAV). Not terminal-decline — the underlying business is structurally supported — but the market is pricing in real balance-sheet risk.

Earnings vs. expectations

The filings do not consistently disclose specific analyst consensus figures, but management guidance and delivery can be tracked. In FY 2025, management guided to £9m of Assura synergies; H1 2026 shows 92% delivered ahead of schedule — a beat. Adjusted EPS 3.8p in H1 2026 vs 3.5p in H1 2025 (+9%) is broadly in line with the "sector leading rental growth >3%" strategic framework — met to modest beat. Dividend has grown for 30 consecutive years and cover has moved from 100% to 103% — beat on cover. Overall pattern: consistent delivery of small operational beats, but the market has not rewarded them because balance-sheet concerns dominate.

Conviction

Conviction: 4 — high.

Anchoring factors: (i) NAV-based valuation is the dominant methodology for a REIT and the reported Adjusted NTA of 104p is independently valued by four Red Book valuers with strong disclosure; (ii) the income stream is unusually predictable (76% government-backed, 99% occupied, 10-year WAULT); (iii) the dividend yield cross-check gives a consistent range.

Limiting factors: (i) NIY sensitivity — a 25bp yield shift moves NAV by ~10p, so if UK gilts sell off further the fair value range could compress; (ii) execution risk on the private-hospital JV, which is central to deleveraging and to the credit rating case.

Overall score rationale

For the investor profile described:

• AI-receiver alignment: essentially zero. Healthcare REITs have no meaningful position in the AI value chain — this is a passive infrastructure landlord.
• Operating leverage: modest, capped by contractual rent-review mechanics.
• Valuation discipline: passes. Trading at a modest discount to NAV; no bull-case is required.
• Downside protection: mixed. Business quality is genuinely defensive, but 57% LTV / 10.4x Net Debt/EBITDA is materially above what the investor profile calls "fortress balance sheet."

This is a defensive income stock, not an AI-receiver, and lacks the long-tail upside the strategy targets. Score sits in the 200–300 band.

Overall score: 240 / 1000.